PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$117.23
as of August 19, 2026 -
YTD RETURNS15.26%
as of August 19, 2026 -
Total Net Assets$1.02B
as of August 19, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 1.42 | 8.94 | 8.49 | 35.82 | 13.41 | 10.23 | 7.99 | 10.19 |
| PPH (Market Price) | 1.53 | 9.00 | 8.49 | 35.95 | 13.43 | 10.23 | 7.99 | 10.27 |
| MVIS US Listed Pharmaceutical 25 Index | 1.46 | 8.88 | 8.28 | 35.59 | 13.04 | 9.86 | 7.74 | 10.00 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 08/19/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.16 |
214,771,914 |
|
MRK |
Merck & Co Inc |
10.89 |
115,971,986 |
|
NVS |
Novartis Ag |
10.15 |
108,092,705 |
|
PFE |
Pfizer Inc |
4.93 |
52,567,659 |
|
BMY |
Bristol-Myers Squibb Co |
4.90 |
52,152,055 |
|
NVO |
Novo Nordisk A/S |
4.86 |
51,739,491 |
|
ABBV |
Abbvie Inc |
4.51 |
48,087,908 |
|
JNJ |
Johnson & Johnson |
4.38 |
46,622,693 |
|
MCK |
Mckesson Corp |
4.35 |
46,319,743 |
|
GSK |
Gsk Plc |
4.16 |
44,321,425 |
|
SNY |
Sanofi Sa/France |
4.02 |
42,778,501 |
|
AZN |
Astrazeneca Plc |
3.52 |
37,487,362 |
|
COR |
Cencora Inc |
3.51 |
37,399,725 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
3.16 |
33,634,009 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.07 |
32,675,718 |
|
HLN |
Haleon Plc |
3.05 |
32,517,070 |
|
ZTS |
Zoetis Inc |
2.09 |
22,271,629 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.06 |
11,246,084 |
|
VTRS |
Viatris Inc |
1.05 |
11,140,415 |
|
CORT |
Corcept Therapeutics Inc |
0.64 |
6,860,194 |
|
AXSM |
Axsome Therapeutics Inc |
0.64 |
6,806,094 |
|
ELAN |
Elanco Animal Health Inc |
0.33 |
3,496,983 |
|
OGN |
Organon & Co |
0.22 |
2,310,635 |
|
BHC |
Bausch Health Cos Inc |
0.13 |
1,360,555 |
|
PRGO |
Perrigo Co Plc |
0.08 |
802,923 |
|
-USD CASH- |
-- |
0.00 |
1,826 |
|
-- |
Other/Cash |
0.18 |
1,950,483 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 07/31/2026
-
Sector
% of Net Assets -
Health Care
99.95 -
Other/Cash
0.05
Country Weightings (%) as at 07/31/2026
-
Country
% of Net Assets -
United States
62.64 -
United Kingdom
11.41 -
Switzerland
10.50 -
Denmark
5.23 -
France
4.01 -
Israel
3.13 -
Japan
3.04 -
Other/Cash
0.05
Fees
Distributions
as of 08/19/2026
Quarterly
1.84%
2.13%
1.85%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency